WO2005011620A3 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content - Google Patents

Methods and apparatus for creating particle derivatives of hdl with reduced lipid content Download PDF

Info

Publication number
WO2005011620A3
WO2005011620A3 PCT/US2004/006988 US2004006988W WO2005011620A3 WO 2005011620 A3 WO2005011620 A3 WO 2005011620A3 US 2004006988 W US2004006988 W US 2004006988W WO 2005011620 A3 WO2005011620 A3 WO 2005011620A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdl
cholesterol
methods
derivatives
lipid content
Prior art date
Application number
PCT/US2004/006988
Other languages
French (fr)
Other versions
WO2005011620A2 (en
Inventor
Marc Bellotti
H Bryan Brewer Jr
Hassibullah Akeefe
Adam Paul Conner
Timothy Jon Perlman
Original Assignee
Lipid Sciences Inc
Marc Bellotti
H Bryan Brewer Jr
Hassibullah Akeefe
Adam Paul Conner
Timothy Jon Perlman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipid Sciences Inc, Marc Bellotti, H Bryan Brewer Jr, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman filed Critical Lipid Sciences Inc
Priority to ES04718501T priority Critical patent/ES2715496T3/en
Priority to AU2004260632A priority patent/AU2004260632A1/en
Priority to DK04718501.2T priority patent/DK1641421T3/en
Priority to EP04718501.2A priority patent/EP1641421B1/en
Priority to CA002531227A priority patent/CA2531227A1/en
Priority to JP2006518606A priority patent/JP2007527387A/en
Publication of WO2005011620A2 publication Critical patent/WO2005011620A2/en
Publication of WO2005011620A3 publication Critical patent/WO2005011620A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Abstract

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
PCT/US2004/006988 2003-07-03 2004-03-08 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content WO2005011620A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES04718501T ES2715496T3 (en) 2003-07-03 2004-03-08 Methods and apparatus for creating derivatives of HDL particles with a reduced lipid content
AU2004260632A AU2004260632A1 (en) 2003-07-03 2004-03-08 Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
DK04718501.2T DK1641421T3 (en) 2003-07-03 2004-03-08 Methods and apparatus for producing HDL particle derivatives of reduced lipid content
EP04718501.2A EP1641421B1 (en) 2003-07-03 2004-03-08 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
CA002531227A CA2531227A1 (en) 2003-07-03 2004-03-08 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
JP2006518606A JP2007527387A (en) 2003-07-03 2004-03-08 Method and apparatus for producing particle derivatives of HDL with reduced lipid content

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48469003P 2003-07-03 2003-07-03
US60/484,690 2003-07-03

Publications (2)

Publication Number Publication Date
WO2005011620A2 WO2005011620A2 (en) 2005-02-10
WO2005011620A3 true WO2005011620A3 (en) 2006-05-18

Family

ID=34115319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006988 WO2005011620A2 (en) 2003-07-03 2004-03-08 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content

Country Status (9)

Country Link
US (5) US7375191B2 (en)
EP (2) EP2368565B1 (en)
JP (1) JP2007527387A (en)
AU (1) AU2004260632A1 (en)
CA (1) CA2531227A1 (en)
DK (2) DK1641421T3 (en)
ES (2) ES2547547T3 (en)
PT (2) PT1641421T (en)
WO (1) WO2005011620A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
PT1641421T (en) * 2003-07-03 2019-03-27 Hdl Therapeutics Inc Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
EP1685852A1 (en) * 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
JP2009502933A (en) * 2005-07-27 2009-01-29 リピッド サイエンシーズ，インコーポレイテッド Methods of treating cancer cells to generate modified cancer cells that elicit an immunogenic response
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
ITMO20060097A1 (en) * 2006-03-24 2007-09-25 Giuseppe Zucca DEVICE AND METHOD FOR DILUTION AND PREPARATION OF ANTIBLASTIC DRUGS
US8785382B2 (en) * 2006-04-03 2014-07-22 Abbott Cardiovascular Systems Inc. Lipid therapy
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
EP2488228A4 (en) * 2009-10-18 2018-03-21 Glycorex AB Method and product for blood treatment and purification
ES2532006T3 (en) * 2009-11-20 2015-03-23 Pharnext New diagnostic tools for Charcot-Marie-Tooth disease
MX343907B (en) 2011-02-07 2016-11-28 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof.
US10624924B2 (en) * 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders
MX2016014306A (en) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Hdl therapy markers.
AU2015201496B2 (en) 2014-06-03 2019-10-31 Grifols Worldwide Operations Limited Use of plasmapheresis to treat blood pressure disorders
CA3051237A1 (en) * 2017-01-23 2018-07-26 Hdl Therapeutics, Inc. Methods for treating cholesterol-related diseases
CN110545797A (en) * 2017-03-01 2019-12-06 Hdl治疗公司 Methods of prophylactically preventing, slowing progression of, or treating alzheimer's disease
CN111868232A (en) 2017-11-22 2020-10-30 Hdl治疗公司 System and method for priming a fluid circuit of a plasma processing system
CN112040932A (en) 2017-12-28 2020-12-04 Hdl治疗公司 Method for preserving and administering pre-beta high density lipoproteins extracted from human plasma
JP2021523182A (en) * 2018-05-11 2021-09-02 エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Methods for Preventing, Delaying, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and / or Acute Stroke

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647624A (en) 1969-07-24 1972-03-07 Wisconsin Alumni Res Found Treatment of blood with oleaginous substance
US3989466A (en) 1973-08-13 1976-11-02 Pan Samuel C Liquid-liquid extraction apparatus including fibrous strand packing
JPS5328989B2 (en) 1974-05-27 1978-08-17
US3983028A (en) * 1974-07-01 1976-09-28 Standard Oil Company (Indiana) Process for recovering upgraded products from coal
US3958939A (en) 1975-01-08 1976-05-25 Coulter Electronics, Inc. Method for clarification of lipemic serum
DE2501376A1 (en) 1975-01-15 1976-07-22 Metallgesellschaft Ag METHOD FOR REMOVING MONOPHENOLS, DIPHENOLS AND THE LIKE FROM WASTEWATERS
US4258010A (en) 1975-11-19 1981-03-24 Eszakmagyarorszagi Vegyimu_ vek Solvent extraction apparatus
JPS5272379A (en) 1975-12-15 1977-06-16 Toray Ind Inc Separation of fluid
US4103685A (en) 1976-01-05 1978-08-01 Lupien Paul J Method and apparatus for extravascular treatment of blood
DE2710241A1 (en) 1976-03-11 1977-09-22 Krebs & Co Ag PROCESS FOR MIXING AND SEPARATING TWO IMMISCABLE LIQUIDS
JPS5549791Y2 (en) 1976-04-21 1980-11-20
US4671909A (en) 1978-09-21 1987-06-09 Torobin Leonard B Method for making hollow porous microspheres
JPS55127104A (en) * 1979-03-23 1980-10-01 Seikouen Hosono Shinriyoushiyo Method for continuous extraction of minor component and device therefor
FR2455743A1 (en) 1979-05-02 1980-11-28 Goella Laboratoires METHOD AND DEVICE FOR DETERMINING SERUM LIPOPROTEINS
US4234317A (en) 1979-05-24 1980-11-18 Analytical Products, Inc. Apparatus and method for fractionation of lipoproteins
DE2944138A1 (en) * 1979-11-02 1981-06-11 Technicon Gmbh, 6368 Bad Vilbel Automatic analysis of separation of deposits from liquids - is by extracting fraction of flowing segmented sample following sedimentation
DE2949907A1 (en) * 1979-12-12 1981-06-19 Hoechst Ag, 6230 Frankfurt FLUOROPOLYMERS WITH SHELL-MODIFIED PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
FR2475572A1 (en) 1980-02-11 1981-08-14 Pasteur Institut PROCESS FOR OBTAINING LIPID ENVELOPE VIRUS FRAGMENTS, PARTICULARLY ANTIGENS USED AS VACCINES, PRODUCTS OBTAINED AND APPLICATIONS
EP0036283A3 (en) 1980-03-19 1982-03-31 DAVY MCKEE (MINERALS & METALS) LIMITED Method and apparatus for liquid-liquid extraction
US4311586A (en) * 1980-04-22 1982-01-19 Tracor, Inc. Solvent mixing in HPLC using low pressure solvent metering pumps
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
DE3118072A1 (en) * 1981-05-07 1982-11-25 Claus-Christian Dr.Rer.Nat. Dr.Med. 6901 Wilhelmsfeld Heuck Process for separating lipophilic constituents from aqueous colloid solutions for preparative purposes and/or for detecting an analyte in the aqueous phase
EP0074610B1 (en) 1981-09-10 1987-05-20 Intermedicat GmbH Method for the selective extracorporeal precipitation of low-density lipoproteins from serum or plasma
US4435289A (en) 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
JPS58155865A (en) 1982-03-12 1983-09-16 株式会社クラレ Hollow yarn membrane for treating serum
DE3213390A1 (en) * 1982-04-10 1983-10-20 Dieter 3000 Hannover Biela DEVICE FOR ACCOUNTING FOR LIQUID EXCHANGE IN HAEMOFILTRATIONS
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
EP0101066B1 (en) 1982-08-14 1988-12-21 Gustav E. Dr. Phil. Utzinger Liquid-spraying system
US4463988A (en) 1982-09-07 1984-08-07 Cities Service Co. Horizontal heated plane process
SU1204224A1 (en) * 1982-12-30 1986-01-15 Казанский Ордена Трудового Красного Знамени Химико-Технологический Институт Им.С.М.Кирова Centrifugal extractor
US4540401A (en) 1983-02-22 1985-09-10 Applied Immune Sciences, Inc. In vivo therapeutic apheresis using lipid vesicles
US4643718A (en) 1983-02-22 1987-02-17 Applied Immunesciences, Inc. Therapeutic apheresis
DE3310263A1 (en) * 1983-03-22 1984-09-27 Fresenius AG, 6380 Bad Homburg Process for eliminating lipophilic substances from aqueous solutions and apparatus for carrying out the process
DE3310727A1 (en) 1983-03-24 1984-10-04 B. Braun Melsungen Ag, 3508 Melsungen METHOD AND DEVICE FOR SELECTIVE, EXTRACORPORAL SEPARATION OF PATHOLOGICAL AND / OR TOXIC BLOOD COMPONENTS
SU1116396A1 (en) * 1983-05-23 1984-09-30 2-Й Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова Method of removing cholesterol from blood
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4668398A (en) 1983-07-21 1987-05-26 Colgate-Palmolive Company Continuous extraction apparatus and process
US4615886A (en) 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
GB8330094D0 (en) * 1983-11-11 1983-12-21 Ici Plc Diphenyl compounds
JPS60231613A (en) 1984-04-28 1985-11-18 Terumo Corp Method for separating humoral component, separation material and separation apparatus therefor
DE3422407A1 (en) 1984-06-16 1986-03-06 B. Braun Melsungen Ag, 3508 Melsungen USE OF HEPARINE DERIVATIVES FOR SELECTIVE EXTRA-CORPORAL PRECIPITATION OF LOW-DENSITY-LIPOPROTEINS FROM FULL SERUM OR PLASMA
DE3422494A1 (en) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen METHOD AND DEVICE FOR SPECIFIC ADSORPTION OF HEPARIN
EP0168093B1 (en) 1984-06-27 1988-11-23 Organon Teknika B.V. Binder for low density lipoproteins
FR2571971B1 (en) * 1984-10-23 1988-12-02 Haas Thierry DEVICE USING ELASTINE TO LOWER THE CONCENTRATION OF LIPID CONSTITUENTS OF A LIQUID.
JPS61119271A (en) 1984-11-13 1986-06-06 鐘淵化学工業株式会社 Blood component treatment circuit and method
DE3568442D1 (en) 1984-12-06 1989-04-06 Kanegafuchi Chemical Ind A method of preparation of droplets
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4677057A (en) 1985-03-11 1987-06-30 Scripps Clinic And Research Foundation Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
US4675905A (en) * 1985-04-12 1987-06-23 Ampex Corporation Multiple input silent audio switch
US4645512A (en) 1985-05-06 1987-02-24 The Dow Chemical Company Continuous process for removing water-soluble particles from organic liquids
US4895558A (en) * 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
CA1259915A (en) 1985-10-09 1989-09-26 Sailen S. Mookerjea Means to reduce plasma cholesterol
US4832928A (en) * 1985-10-15 1989-05-23 Thermal Science, Inc. Method for producing ammonium polyphosphate
DE3682482D1 (en) * 1985-11-22 1991-12-19 Schweiz Serum & Impfinst METHOD FOR PRODUCING A RABBIT VACCINE AND VACCINE OBTAINED BY THIS PROCESS.
US5080796A (en) 1985-12-19 1992-01-14 The Cleveland Clinic Foundation Thermofiltration of plasma
US4966709A (en) 1985-12-19 1990-10-30 The Cleveland Clinic Foundation Thermofiltration of plasma
US5203778A (en) 1986-02-18 1993-04-20 Boehringer Laboratories Process and apparatus for removal of insoluble fat from blood of a patient
US5354262A (en) 1986-02-18 1994-10-11 Boehringer Laboratories Apparatus for removal of insoluble fat from blood of a patient
US4836034A (en) * 1986-07-15 1989-06-06 Ricoh Company, Ltd. Force sensing apparatus
US5126240A (en) 1986-09-29 1992-06-30 Curtiss Linda K Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i
US4855113A (en) * 1986-10-27 1989-08-08 Pennwalt Corporation Apparatus for removing sulfur from organic polysulfides
US4832034A (en) 1987-04-09 1989-05-23 Pizziconi Vincent B Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
DE3854940T2 (en) * 1987-05-20 1996-07-11 Rogosin Inst RECONSTRUCTED HDL PARTICLES AND THEIR USE
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
JPH0829316B2 (en) 1987-10-16 1996-03-27 田辺製薬株式会社 How to remove Pyrogen
US5055396A (en) * 1987-11-03 1991-10-08 Scripps Clinic And Research Foundation Diagnostic methods and systems for quantifying apo ai
EP0476721B1 (en) * 1987-11-20 1995-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha A method for removing serum amyloid protein
US5112956A (en) 1987-12-02 1992-05-12 The Nutrasweet Company Method for extraction of lipids and cholesterol
US4909940A (en) 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
DE8802722U1 (en) * 1988-03-01 1988-04-14 Industrial Technology Research Institute, Hsinchu, Tw
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5152743A (en) 1988-08-05 1992-10-06 Healthdyne, Inc. Apparatus and method for selective separation of blood cholesterol
US5419759A (en) 1988-11-17 1995-05-30 Naficy; Sadeque S. Apparatus and methods for treatment of HIV infections and AIDS
US5484396A (en) 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
US5026479A (en) 1990-02-13 1991-06-25 Union Carbide Industrial Gases Technology Corporation Fluid separation device
DE4018778A1 (en) 1990-06-12 1991-12-19 Braun Melsungen Ag ADSORPTION MATERIAL FOR THE SELECTIVE REMOVAL OF LDL AND / AND VLDL
US5116307A (en) 1990-07-09 1992-05-26 Collins Harvey T Method and system for treatment of AIDS
US5418061A (en) 1990-11-27 1995-05-23 W. R. Grace & Co.-Conn. Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
US5187010A (en) 1990-11-27 1993-02-16 W. R. Grace & Co.-Conn. Membrane having high affinity for low density lipoprotein-cholesterol from whole blood
US5258149A (en) 1990-11-27 1993-11-02 W. R. Grace & Co.-Conn. Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood
US5236644A (en) 1990-11-27 1993-08-17 W. R. Grace & Co.-Conn. Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood
SU1752187A3 (en) * 1990-12-11 1992-07-30 А.Б.Сигалов Method for delipidation of lyophilized lipoproteins of high density from human blood serum
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US5211850A (en) 1991-07-26 1993-05-18 Research Medical, Inc. Plasma filter sorbent system for removal of components from blood
JP2576744B2 (en) 1991-11-05 1997-01-29 日揮株式会社 Liquid-liquid contact tower
US5301694A (en) 1991-11-12 1994-04-12 Philip Morris Incorporated Process for isolating plant extract fractions
US5391429A (en) * 1992-01-07 1995-02-21 Diafoil Hoechst Company, Limited Polyester film
US5919369A (en) 1992-02-06 1999-07-06 Hemocleanse, Inc. Hemofiltration and plasmafiltration devices and methods
ATE193603T1 (en) 1992-02-24 2000-06-15 Coulter Corp SUSPENSION MEDIA FOR HEMATOLIGIC COMPOSITIONS AND METHOD FOR THEIR USE
ATE194921T1 (en) 1992-03-02 2000-08-15 Bioeng Inc METHOD FOR INACTIVATION OF VIRUSES
JP2744546B2 (en) * 1992-04-01 1998-04-28 株式会社栃本天海堂 Solid extractor
US5279540A (en) 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
IL104015A0 (en) 1992-12-07 1993-05-13 Doina International Ltd P Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
US5391143A (en) 1993-03-12 1995-02-21 Kensey Nash Corporation Method and system for effecting weight reduction of living beings
CA2156721C (en) 1993-03-16 1999-06-01 Thomas B. Okarma Removal of selected factors from whole blood or its components
US5401466A (en) 1993-06-01 1995-03-28 Miles Inc. Device for the direct measurement of low density lipoprotein cholesterol
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
CA2168470C (en) * 1993-07-30 2008-03-18 Bill Elliot Cham A plasma delipidation system
ATA159993A (en) 1993-08-10 1995-09-15 Dieter Dr Falkenhagen ARRANGEMENT FOR ELIMINATING SUBSTANCES FROM LIQUIDS
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
DE69528652D1 (en) 1994-06-22 2002-11-28 Fls Miljoe As Valby MASS TRANSFER DEVICE
US5962322A (en) 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US5637224A (en) 1994-09-14 1997-06-10 New Jersey Institute Of Technology Hollow fiber contained liquid membrane pervaporation for removal of volatile organic compounds from aqueous solutions
DE4435612A1 (en) 1994-10-05 1996-04-11 Braun Melsungen Ag Process for the simultaneous removal of tumor necrosis factor alpha and bacterial lipopolysaccharides from an aqueous liquid
AUPN030794A0 (en) * 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
US5634893A (en) 1995-04-24 1997-06-03 Haemonetics Corporation Autotransfusion apparatus
JP3595608B2 (en) * 1995-05-30 2004-12-02 アネルバ株式会社 Vacuum processing apparatus, method for removing deposited film on inner surface of vacuum vessel in vacuum processing apparatus, and method for uniforming film deposition on inner surface of vacuum vessel in vacuum processing apparatus
US5719194A (en) 1995-08-22 1998-02-17 Ausimont S.P.A. Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof
US5911698A (en) 1995-12-22 1999-06-15 Aruba International Pty. Ltd. Treatment for cardiovascular and related diseases
EP0892664A4 (en) 1996-03-08 1999-09-15 Baxter Research Medical Inc Selective membrane/sorption techniques for salvaging blood
US6171373B1 (en) * 1996-04-23 2001-01-09 Applied Ceramics, Inc. Adsorptive monolith including activated carbon, method for making said monolith, and method for adsorbing chemical agents from fluid streams
DK0915906T3 (en) * 1996-07-10 2000-11-20 American Nat Red Cross Methods for selectively separating organic components from biological fluids
WO1998009602A2 (en) 1996-09-05 1998-03-12 The Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
US5707673A (en) 1996-10-04 1998-01-13 Prewell Industries, L.L.C. Process for extracting lipids and organics from animal and plant matter or organics-containing waste streams
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6605588B1 (en) * 1996-11-27 2003-08-12 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
TW318283B (en) * 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
AT405939B (en) 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US6022333A (en) * 1997-05-01 2000-02-08 S.L.I.M. Tech, Ltd. Method and system for removing materials from lymphatic and other fluids
WO1998055224A1 (en) * 1997-06-03 1998-12-10 Kaneka Corporation Lipoprotein adsorbent and lipoprotein adsorber made with the use of the same
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US5980478A (en) 1997-10-10 1999-11-09 Transvivo, Inc. Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration
CN1070380C (en) * 1997-12-30 2001-09-05 长春市中心血站 Application and prodn. method of HDL preparation
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
US20020055529A1 (en) * 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
JP2002533169A (en) * 1998-12-29 2002-10-08 オキュロジックス コーポレイション Rheological treatment method and associated apheresis system
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AUPQ486699A0 (en) 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
CA2417744A1 (en) 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
AU2002213137A1 (en) 2000-10-11 2002-04-22 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
WO2002062824A2 (en) 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid ? precursor disorder
US6706008B2 (en) * 2001-03-06 2004-03-16 Baxter International Inc. Automated system and method for withdrawing compounds from blood
US20030104350A1 (en) * 2001-06-25 2003-06-05 Bomberger David C. Systems and methods using a solvent for the removal of lipids from fluids
JP2005538148A (en) * 2002-08-26 2005-12-15 リピド サイエンスィズ インコーポレイテッド Treatment of Alzheimer's disease using defatted protein particles
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
PT1641421T (en) * 2003-07-03 2019-03-27 Hdl Therapeutics Inc Methods and apparatus for creating particle derivatives of hdl with reduced lipid content

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAY ET AL: "Formation of apolipoprotein high density lipoprotein particles form lipid-free apolipoprotiens A-I and A-II.", BIOCHEM J., vol. 337, September 2000 (2000-09-01), pages 455 - 451, XP002996450 *
DURBIN ET AL: "Lipid-free apolipoproteins A-I and A-II promote remodeling of reconstituted high density lipoproteins and alter their reactivity with lecithin:cholesterol acyltransferase.", J LIPID RES., vol. 40, September 1999 (1999-09-01), pages 2293 - 2302, XP002996451 *
See also references of EP1641421A4 *
TRICERRI ET AL: "Interaction of apolipoprotein A-I in three different conformations with palmitoyl oleoyl phosphatidylcholine vesicles.", J LIPID RES., vol. 43, November 2002 (2002-11-01), pages 187 - 197, XP002996452 *

Also Published As

Publication number Publication date
US20050004004A1 (en) 2005-01-06
US20050090444A1 (en) 2005-04-28
EP1641421B1 (en) 2018-12-26
US20080234621A1 (en) 2008-09-25
US7361739B2 (en) 2008-04-22
EP1641421A4 (en) 2006-10-18
DK2368565T3 (en) 2015-09-28
AU2004260632A1 (en) 2005-02-10
US20080214438A1 (en) 2008-09-04
US20080230465A1 (en) 2008-09-25
PT1641421T (en) 2019-03-27
CA2531227A1 (en) 2005-02-10
ES2547547T3 (en) 2015-10-07
EP2368565B1 (en) 2015-06-24
DK1641421T3 (en) 2019-03-11
ES2715496T3 (en) 2019-06-04
EP2368565A1 (en) 2011-09-28
US7375191B2 (en) 2008-05-20
JP2007527387A (en) 2007-09-27
PT2368565E (en) 2015-10-19
US8048015B2 (en) 2011-11-01
EP1641421A2 (en) 2006-04-05
WO2005011620A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2005011620A3 (en) Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
Gotto Jr et al. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data Issues from the interdisciplinary council on reducing the risk for coronary heart disease, ninth council meeting
Gierman et al. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE* 3Leiden. CETP mice—a translational model for atherosclerosis
Gotto Jr Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin
Isaacsohn et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
Tamura et al. Nicorandil, a Katp channel opener, alleviates chronic renal injury by targeting podocytes and macrophages
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
MXPA03002964A (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases.
Richter et al. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long‐term evaluation
Borberg 26 years of LDL–apheresis: a review of experience
Zinellu et al. Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease
Al-Quobaili et al. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major
Esmon What did we learn from new oral anticoagulant treatment?
Rideout et al. Combination drug–diet therapies for dyslipidemia
Schettler et al. How to optimize lipoprotein apheresis treatment–a second look
Kosmidis et al. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study
Shavit et al. Atrial myxoma presenting with total occlusion of the abdominal aorta and multiple peripheral embolism
RU2009116632A (en) KETOCONAZOLE ENANTIOMER IN PEOPLE
McKenney Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction
Ballantyne Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction
Gälman et al. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency
Oztuna et al. The effect of pentoxifylline in treatment of skin degloving injuries: an experimental study
McKoy et al. Investigation of the effects of a sapogenin-rich preparation from a Jamaican yam (Dioscorea sp.) on blood cholesterol levels in rats
Aikpokpo et al. Management of the Failing Kidney Transplant: Challenges and Solutions
Olszewska-Banaszczyk et al. Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004718501

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006518606

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004260632

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2531227

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004260632

Country of ref document: AU

Date of ref document: 20040308

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004260632

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004718501

Country of ref document: EP